Key Points
- CEO John Kao sold 250,000 shares on April 7 at an average price of $21.01 (about $5.25M) under a pre‑arranged Rule 10b5‑1 plan, reducing his stake by 10.62% to 2,104,641 shares valued at roughly $44.22M.
- Alignment reported Q results that beat EPS estimates (‑$0.05 vs. ‑$0.15) and generated $1.01B in revenue (up 44.4% YoY); analysts have an average rating of "Moderate Buy" with a mean price target of $24.75.
- Institutional ownership is high at about 86.2%, with recent stake increases by firms including Goldman Sachs, RBC and UBS, and a new position added by Woodline Partners.
Alignment Healthcare, Inc. (NASDAQ:ALHC - Get Free Report) CFO James Head sold 11,100 shares of the business's stock in a transaction on Tuesday, April 7th. The stock was sold at an average price of $21.08, for a total value of $233,988.00. Following the completion of the transaction, the chief financial officer directly owned 173,495 shares of the company's stock, valued at approximately $3,657,274.60. The trade was a 6.01% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Alignment Healthcare Trading Down 1.6%
ALHC opened at $21.31 on Thursday. The firm has a market cap of $4.35 billion, a price-to-earnings ratio of -2,128.87, a PEG ratio of 2.74 and a beta of 1.20. The company has a current ratio of 1.71, a quick ratio of 1.71 and a debt-to-equity ratio of 1.80. Alignment Healthcare, Inc. has a 12 month low of $11.63 and a 12 month high of $23.87. The stock has a fifty day moving average price of $19.36 and a 200-day moving average price of $18.97.
Alignment Healthcare (NASDAQ:ALHC - Get Free Report) last released its quarterly earnings results on Thursday, February 26th. The company reported ($0.05) EPS for the quarter, topping the consensus estimate of ($0.15) by $0.10. The firm had revenue of $1.01 billion during the quarter, compared to analyst estimates of $1 billion. Alignment Healthcare had a negative return on equity of 0.49% and a negative net margin of 0.02%.The business's revenue for the quarter was up 44.4% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.16) EPS. As a group, equities research analysts anticipate that Alignment Healthcare, Inc. will post -0.69 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
Several hedge funds have recently added to or reduced their stakes in ALHC. Royal Bank of Canada increased its position in Alignment Healthcare by 92.6% during the 1st quarter. Royal Bank of Canada now owns 92,379 shares of the company's stock valued at $1,720,000 after buying an additional 44,413 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Alignment Healthcare by 4.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 59,557 shares of the company's stock valued at $1,109,000 after buying an additional 2,594 shares in the last quarter. Goldman Sachs Group Inc. increased its position in Alignment Healthcare by 79.1% during the 1st quarter. Goldman Sachs Group Inc. now owns 972,715 shares of the company's stock valued at $18,112,000 after buying an additional 429,703 shares in the last quarter. Woodline Partners LP acquired a new position in Alignment Healthcare during the 1st quarter valued at about $2,142,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in Alignment Healthcare by 16.9% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 307,655 shares of the company's stock valued at $5,729,000 after buying an additional 44,452 shares in the last quarter. 86.19% of the stock is owned by institutional investors and hedge funds.
Analyst Ratings Changes
Several research firms have recently commented on ALHC. Robert W. Baird set a $28.00 price target on Alignment Healthcare in a research report on Friday, January 30th. TD Cowen boosted their price target on Alignment Healthcare from $18.50 to $25.00 and gave the stock a "buy" rating in a research report on Friday, January 16th. Piper Sandler upped their target price on Alignment Healthcare from $20.00 to $30.00 and gave the company an "overweight" rating in a research report on Tuesday, January 6th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Alignment Healthcare in a research report on Wednesday, January 21st. Finally, KeyCorp reaffirmed an "overweight" rating and set a $28.00 target price on shares of Alignment Healthcare in a research report on Thursday, January 22nd. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $24.75.
Get Our Latest Stock Analysis on Alignment Healthcare
Alignment Healthcare Company Profile
(
Get Free Report)
Alignment Healthcare, Inc (NASDAQ: ALHC) is a health care company specializing in value-based care for Medicare Advantage beneficiaries. The company leverages an integrated care model that combines in-home clinical services, telehealth capabilities and digital health tools to manage chronic conditions, improve outcomes and enhance patient experience.
At the core of Alignment Healthcare's approach is a proprietary technology platform that aggregates real-time clinical and claims data to support preventive care, risk stratification and personalized care plans.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
